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In this paper, we sought to identify the CD4+ T-cell dynamics in the course of HIV infection in response to
continuous and intermittent intravenous courses of interleukin-2 (IL-2), the principal cytokine respon-
sible for progression of CD4+ T-lymphocytes from the G1 to the S phase of the cell cycle. Based on
multivariate regression models, previous literature has concluded that the increase in survival of CD4+
T-cell appears to be the critical mechanism leading to sustained CD4+ T-cell levels in HIV-infected
patients receiving intermittent IL-2 therapy. Underscored by comprehensive mathematical modeling, a
major ﬁnding of the present work is related to the fact that, rather than due to any increase in survival of
CD4+ T-cells, the expressive, selective and sustained CD4+ T-cell expansions following IL-2 administra-
tion may be related to the role of IL-2 in modulating the dynamics of Fas-dependent apoptotic pathways,
such as activation-induced cell death (AICD) or HIV-speciﬁc apoptotic routes triggered by viral proteins.
& 2013 Elsevier Ltd. All rights reserved.1. Introduction
Restoration and preservation of the CD4+ T-cell count remain
crucial in the successful clinical management of the human
immunodeﬁciency virus (HIV) infection (Kovacs et al., 1995). Inll rights reserved.
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sp.br (M. Joly),this regard, attempts to improve immunological functions have
considered a variety of immune-based therapies (Kovacs et al.,
1995; Dybul et al., 2003), including interleukin-2 (IL-2), a T-cell-
derived lymphokine with several immunomodulating effects
including the progression of CD4+ T-cells from the G1 to the S
phase of the cell cycle.
IL-2 is a 14–17 kDa glycoprotein encoded by a single gene on
chromosome 4 and has been considered a valid anti-HIV ther-
apeutic option in the clinical arena, since several clinical phase I/II
studies have demonstrated that intermittent subcutaneous or
continuous intravenous administration of IL-2 in asymptomatic
HIV-infected patients may induce a substantial, selective and
sustained expansion of CD4+ T-lymphocytes, the major HIV target
(Kovacs et al., 1995, 1996; Dybul et al., 2003; De Paoli, 2001; Levy
et al., 2003; Sereti et al., 2007; Read et al., 2008; INSIGHT-ESPIRIT,
2009).
However, the mechanisms leading to these increases remain
unknown (Markowitz et al., 2012). The complexity of the in vivo
cytokine network renders the interpretation of the role of indivi-
dual cytokines in HIV pathogenesis quite difﬁcult, since the role of
M. Joly, D. Odloak / Journal of Theoretical Biology 335 (2013) 57–7858HIV-induced dysregulation of cytokine networks in disease patho-
genesis is likely multifactorial; many of the dysfunction in cyto-
kine production, such as the increases in proinﬂammatory
cytokines, favor viral replication whereas others, such as the
decrease in IL-2 production, have effects that are less clear
(Dybul et al., 2003). Since a major concern with the use of IL-2
was the theoretical risk that this cytokine could stimulate HIV
replication (Levy et al., 2003), the mechanisms underlying the
immunological effects of IL-2 therapy have been widely investi-
gated in the last decade. Findings based on experimental work
suggest that IL-2 acts through several, sometimes conﬂicting,
mechanisms that are deeply inﬂuenced by (De Paoli, 2001):
(a) the host immunological status, (b) the concomitant highly-
active antiretroviral therapy (HAART) scheme adopted, and (c) the
nature of target cells.
To better understand the association between the CD4+ T-cell
increases seen veriﬁed following IL-2 therapy and key biological
mechanisms thought to be affected by such therapy, we extend our
previous work on comprehensive mathematical modeling of HIV
disease to help us provide further phenomenological interpretation
of the impact of IL-2 on its vertiginous dynamics. In particular, the
goal of the current study was to determine whether there was a
theoretical association between any of the proposed biological
mechanisms in the past, such as preferential expansion and survival
of naïve (CD27+CD45RO−) and central memory (CD27+CD45RO+)
subpopulations of IL-2 receptor chain-expressing (CD25) CD4+ T-cells
(Read et al., 2008), and the magnitude of change in CD4+ T-cell
numbers following a cycle of IL-2.2. Model development
When developing a mathematical model for any complex
biological system, the trade-off between complexity and utility
must be considered. Although conclusive kinetic data on HIV-1
dynamics have been ﬁrst derived on the basis of nonlinear ﬁtting
of simple ODE systems by Ho et al. (1995) and Wei et al. (1995),
the most cited scientiﬁc medical research published in 1995, since
then important conclusions about the dynamics of HIV infection
in vivo have continuously been produced based on more sophis-
ticated models in which distinct types of immune cells are
represented separately (e.g., Perelson and Nelson, 1999). In order
to study the impact of IL-2 therapy on HIV infection, our motiva-
tion to adopt a modeling approach that considers a set of immune
cells phenotypically well characterized relied on the following
major aspects:SourceAPCs from PB: the site of clinical evaluationThe cytokine network that regulates the immune system
dynamics is differentially impacted by the CD4 T-cell pheno-
type (see Section 2.4);peripheral tissues  HIV infection of a CD4 T-cell is a process highly dependent on
the cell phenotype (Joly and Pinto 2005), andAfferent    Immature APCs 
Functional APCs 
Free HIV
Resting T-cells 
Effector T-cells 
Memory T-cells 
LT
Efferent lymphatic 
HEVs 
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Fig. 1. The host anatomic model.Lymphocyte homing and recirculation among anatomic com-
partments is dependent on the cell phenotype.
In this regard, we have, as others (Perelson and Nelson, 1999;
Essunger and Perelson, 1994; Wendelsdorf et al., 2011), modeled
the CD4 T-cell population dynamics as composed by three major
subpopulations: naïve, effector and memory CD4 T-cells. By
focusing on the effector CD4+ T-cell pool resident in the lymphoid
tissues, the model formulation and rationale are presented in the
following seven subsections. The full model structure is summar-
ized in Appendix A, whereas Appendix B lists the model nomen-
clature, their explanation and reference to experimental data.2.1. Transportation, recirculation and homing models
Although high-proﬁle studies have continuously been pub-
lished considering the human body as a single anatomic compart-
ment (Ho et al., 1995; Wei et al., 1995; Perelson and Nelson 1999;
Wendelsdorf et al., 2011; Perelson et al., 1993; Hadjiandreou
et al., 2009), a more realistic representation of the dynamics of
HIV infection in the bloodstream, the usual site for host clinical
monitoring, may be (highly) dependent on endogenous and
exogenous factors acting differentially on each host tissue. In fact,
early events in HIV infection may be intimately related to lym-
phocyte recirculation and homing among anatomic compartments
of the host (Abbas et al., 2000). More importantly, “measuring the
viral load in blood after initiation of antiretroviral treatment does not
provide sufﬁcient information to identify the biological processes
underlying the second phase of viral decline”, as concluded by
Perelson and Nelson (1999).
Aiming at considering some aspects thought to be relevant in
delineating the real-world dynamics of HIV infection in the
peripheral blood (e.g., lymphocyte recirculation and homing, and
differentiated distribution of therapeutic agents among host
tissues), the human body is here represented by three intercon-
nected anatomic compartments well characterized in the context
of HIV disease: the peripheral blood (PB) for clinical evaluation,
the lymphoid tissue (LT), where most HIV replication occurs
(Dybul et al., 2003), and the central nervous system (CNS), which
is also referred as an “HIV sanctuary” or “immunologically privi-
leged” site due to the poor penetration of therapeutic agents or
limited trafﬁc of immune cells through the blood–brain barrier
(BBB) (Dybul et al., 2003; Cohen, 1998). In doing this, we attempt
to consider the impact of the mass transfer associated to the
transportation of immune cells, viral particles and cytokines on
the infection dynamics throughout the human body. The proposed
anatomic model is schematically illustrated in Fig. 1, in which the
arrival of HIV trapped by antigen-presenting cells from the
peripheral tissues into the LT compartment is also taken into
account. This may be the case of sexually transmitted infection, the
major AIDS contagious route (Dybul et al., 2003).
As a result, two types of viral reservoirs are considered. The
ﬁrst one is site-dependent and is modeled by considering that the
mass transfer throughout the BBB is limited by either “mechanical”
restrictions or selective (active) transportation. The second one,
which may arise in any anatomic compartment, is represented by
long-lived immune cells, such as memory T-cells and cells of the
monocyte–macrophage lineage. As in other HIV models, we
hypothesize that long-lived cells, even when infected by HIV, have
an extended period of life.
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are released from the source compartment into the circulation.
These newly exported cells are preferentially recruited to the LT
compartment where their encounter with a foreign antigen
promotes CD4+ T-cell activation and differentiation (Section 2.6).
If naïve CD4+ T-cells that have entered the LT compartment fail to
encounter antigenic stimulation (Section 2.4), they leave the
lymphoid organ through an efferent lymphatic vessel and return
to the blood. Hence, a reasonable model for the naïve CD4+ T-cell
recruitment into the LT compartment could be:
dNL
dt
 !
rec
¼ − dN
P
dt
 !
rec
¼ rL 1− N
L
sN þ NL
 !
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
ð1aÞ
ð1þ hvcVPÞ|ﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄ}
ð1bÞ
NP ð1Þ
where the subscript rec refers to recruitment. In (1), the logistic term
(1a) denotes the return to the PB compartment of LT naïve CD4+
T-cells, NL, that have not been activated within the lymph node due
to rarefaction of antigenic stimulation. We speculate that this may be
the case when the density of CD4+ T-cells inside the LT compartment
is approaching a saturation condition, which is deﬁned by the half-
saturation constant, sN. In (1b), the constant term accounts for the
immune system homeostasis, the property of the immune system
that regulates its internal environment aiming at maintaining a
stable, constant condition that characterizes the host uninfected
state. The homeostatic recruitment of PB naïve CD4+ T-cells, NP, to
the LT compartment is assumed to be a self-regulating process that
can be performed at maximum rate rL. By considering that the
antigenic recognition of plasma HIV, VP, increases the afﬁnity of naïve
CD4+ T-cell integrins to their ligands expressed on the high endothe-
lial venules (HEVs; Fig. 1) (Abbas et al., 2000), the bilinear term
hvcV
PNP is incorporated to (1b) in order to mimic a more efﬁcient
T-cell recruitment to the LT compartment for the infected state. Here,
hvc is the constant rate of encounter between immune cells and
virions. To provide an upper bound on hvc, we use Smoluchowski's
formula (Smoluchowski, 1916) for the diffusion-limited rate constant.
For interaction between two spherical particles of radii RC and RV, and
diffusion coefﬁcients DC and DV, hvc≤4π(RC+RV)(DC+DV) (Perelson
et al., 1993). By assuming RC¼410−4 cm, RV¼5.510−6 cm, DV¼
210−8 cm2 s−1 and DT¼2.510−10 cm2 s−1, we obtain hvc≤1.03
10−10 cm3 s−1¼8.9210−3 mm3 day−1.
Effector CD4+ T-cells produced within the LT compartment by
activation of naïve (or memory) CD4+ T-cells present a broad range
of migratory capacity and are assumed to be actively transported
to the PB and thus to other peripheral compartments. However,
some of the stimulated naïve CD4+ T-cells do not develop into
short-lived effector cells (Section 2.6). Instead, they acquire the
ability to survive for long periods, apparently without antigenic
stimulation or other survival stimuli typically required by effector
CD4+ T-cells. These are memory cells, which are capable of struc-
turing rapid responses to subsequent introduction of antigen.
Since memory T-cells recirculate through the spleen and/or non-
lymphoid tissues (Jenkins, 2003), no active transport mechanism
between the LT and PB compartments is considered, but free
recirculation obeying a saturation condition for the total T-cell
count in the PB is assumed.
In contrast to previous HIV models that consider a hard upper
bound (usually 1500 cells/mm3 (Essunger and Perelson, 1994;
Perelson et al., 1993; Jenkins, 2003)) for the total CD4+ T-cell count
in the PB (TP) aiming at regulating the process of T-cell proliferation,
logistic functions based on half-saturation constants are considered
here. In the proposed recirculation model, the half-saturation con-
stant for TP is chosen as Tmax/2, where Tmax¼1500 cells/mm3, a
higher value than typically reported in healthy individuals (1000
cells/mm3 (Abbas et al., 2000)), but lower than the maximum that
can be obtained in severe infection (Perelson et al., 1993).Concerning the passage of CD4+ T-cells out of the blood into the
CNS, it is well established that this can occur, but only if the T-cell
is activated. Since it is presumed that adhesion molecules would
help leukocytes to cross the BBB (Davson and Segal, 1996), we
assume that the CNS immunity is regulated by the active transport
of immune cells throughout the BBB. This hypothesis is critical to
model homeostatic mechanisms that permit the brain cells to
maintain an environment that ﬂuctuates far less than the blood
plasma and have a speciﬁc composition different from that
surrounding other cells of the body (Davson and Segal, 1996). In
a similar way, the inﬂux of peripheral blood monocytes into the
CNS is assumed to be an active process. Once inside the CNS,
monocytes undergo a series of morphological changes and differ-
entiate into microglia, which may be regarded as an extreme
specialization of the macrophage.
HIV-infected CD4+ T-cells are assumed to be inapt to perform
their immunological functions, being reduced to ordinary sites of
viral replication. Also, no active mechanism is considered to
govern the trafﬁc of HIV-infected lymphocytes among distinct
compartments. As for free viral particles, the redistribution of
HIV-infected CD4+ T-cells from LT to the PB is admitted to be a
passive process dependent on: (a) the blood ﬂow throughout the
LT compartment, (b) the concentration gradient between the
compartments, and (c) the FDC network integrity.
On the other hand, since the perivascular spaces provide some
access from brain parenchyma to the peripheral lymphatic system,
thereby allowing the invasion of foreign antigens such as infectious
virions (Davson and Segal, 1996), the CNS infection by HIV is
assumed to be carried out by diffusion of free virions throughout
the BBB according to a Fick's Law-based model (Fick, 1855). HIV-
infected cells, instead, are not allowed to cross the BBB, since, by
hypothesis, the homing receptor expression is impaired in these cells
and, hence, they fail to perform active transport into brain tissues.
Since IFN-γ can be produced by cytokine Type I-secreting CD4+
T cells (TH1) in the CNS (Davson and Segal, 1996), we assume that
IL-12 can similarly be produced at this specialized compartment
by activated microglia, here modeled as macrophage-like cells. The
cytokine transportation model across the BBB is outlined in
Appendix C. Lastly, we assume that the rate of cytokine elimina-
tion in the CNS is exclusively due to the natural degradation,
which is, in general, a rapid process at the time-scale of minutes
(Stites et al., 1994).
2.2. The FDC network model
During the dichotomy stage in viral burden between the LT and
the PB compartments, there is a progressive shift in the lymphoid
histopathologic pattern from follicular hyperplasia to follicular
involution. A characteristic outcome is the disruption of the FDC
network leading to a decrease in the efﬁciency of viral trapping in
germinal centers and a resultant increase in plasma viraemia
(Dybul et al., 2003).
Since associated with disease progression (Pantaleo et al., 1993)
and emergence of SI viral isolates (Goldstein et al., 1996), we
hypothesize that the rate of FDC degradation is a density-
dependent function of the SI viral burden in the lymphoid tissues
(Pantaleo et al., 1993). This is modeled in (2), where fd∈[0, fd0] is
the dynamical parameter that quantiﬁes the FDC network func-
tional integrity at time t.
f d ¼ f d0ð1−θÞ ð2Þ
with θ¼ kdf SI
VL
sv þ VL
 !
|ﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄ}
ð3aÞ
ð3Þ
PB
LT
IL-12
Source
(thymus/bone marrow)
N
NN
Ep
IFN-γ
Ep
EpEp
IL-2 
Signal I + II
Signal
Signal I
N N
N
(a) (h)
M
E
Signal I + I
CD40-CD40L
(b)
(j)
(g)
(k)
(k)
(c)
(l)
(f)
(d)
(p)
(p)
(o)(e)
(q)
(i)
(m)
Ep
Healthy
T-cells 
Infected 
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HIV 
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Healthy
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Activated healthy 
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(n) (b)
(k)
Fig. 2. The immune system activation model. N: naïve CD4+ T-cells; Ep: proliferat-
ing CD4+ T-cells; E: effector CD4+ T-cells; M: memory CD4+ T-cells; IL-2:
interleukin-2; IL-12: interleukin-12; IFN-γ: interferon-gama; dashed line: cytokine
production/stimulation.
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network at the uninfected state, whereas fd¼0 denotes the
collapse of the FDC architecture, spread of infection to the
systemic circulation and full-blown AIDS. Loss of FDC network
function takes place solely at the infected state and is modeled
through the logistic function θ. Here, such degradation is assumed
to occur at the maximum rate kd whenever the normalized
fraction of SI isolates within the viral population at time t, fSI,
approaches unity and the lymphatic viral load at time t, VL,
saturates according to the logistic term (3a) in which sv denotes
the corresponding half-saturation concentration.
2.3. The cellular generation model
CD4+ T-cells are created at the generative organs of the
lymphoid tissues, such as the thymus, and distributed to other
compartments by the systemic circulation (Fig. 1). While previous
HIV models have considered that new cells are produced at
constant rates (Essunger and Perelson, 1994), here a density-
dependent function is considered aiming at representing situa-
tions when an exceptional demand for production of new blood
cells occurs (Abbas et al., 2000).
Since a subset of CD34+ progenitor cells express CD4 and are
also infectable in vitro with HIV (Akkina et al., 1996), failure of
normal hematopoiesis becomes an obvious candidate mechanism
to account for depletion of CD4+ T-cells during the HIV infection
(Dybul et al., 2003). Here, the disruption of the thymic micro-
environment and function caused by HIV is assumed to be a
process triggered by SI viral strains (Goldstein et al., 1996) and
kinetically driven by the extent of HIV infection in the lymphoid
tissues. Hence, the proposed model for the naïve CD4+ T-cell
production by the body at time t, λN, results in:
λN ¼ λN0 1−
NP
sn þ NP
 !γ !
θ ð4Þ
In (4), λN0 is the maximum production rate of new T-cells by the
thymus, sn is the half-saturation constant for NP and θ is the logistic
function that models the thymus functional integrity at time t in
response to disease progression, as in (3). Lastly, the exponent γ(γ≥1)
is introduced to allow fast thymic responses whenever the density of
naïve CD4+ T-cells in the blood is importantly reduced with respect to
its homeostatic value.
2.4. The immune system activation model
After thymic education and release into the systemic circulation
(Fig. 2a), naïve CD4+ T-cells are selectively recruited to the LT
compartment, in which the cellular activation, proliferation and
differentiation processes take place. To be roused from its survival
program, a naïve CD4+ T-cell requires two signals, which correspond
to multiple engagements between cellular receptors and the major
histocompatibility complex (MHC) or peptide complexes (Signal I) and
B7 molecules (Signal II) expressed on the surface of APCs (Essunger
and Perelson, 1994; Perelson et al., 1993; Abbas et al., 2000; Jenkins,
2003; Stites et al., 1994; Pantaleo et al., 1993; Goldstein et al., 1996;
Tough and Sprent, 2003) (Fig. 2b). Uninfected or infected IFN-γ
stimulated macrophages (Fig. 2c) as well as macrophages activated
by interactions between their CD40 receptors with the CD40 ligand
(CD40L) expressed on uninfected effector CD4+ T-cells (Fig. 2d) are
assumed to perform the APC functionwith enhanced efﬁciency (Abbas
et al., 2000) (Fig. 2e). This is due to the increased expression of MHC
(Signal I) and B7 molecules (Signal II) on the APC surface.
Among the ﬁrst detectable cellular responses after antigen
recognition is the IL-2 secretion by proliferating CD4+ T-cells
(Abbas et al., 2000) (Fig. 2f). In this sense, it is assumed that initialstimulation (Signal I) can alternatively be produced by infected
CD4+ T-cells with expression of the peptide-MHC complex (Fig. 2g)
and Signal II by IL-2 stimulation.
The monocyte–macrophage cell lineage is created in the bone
marrow (Fig. 2h) and selectively recruited to lymphoid tissues
(Fig. 2i). After innate immune reactions triggered by stimulation
from microbial products, monocytes mature and become macro-
phages, which become apt to perform the APC function (Fig. 2j) as
well as other immune functions, as interleukin-12 (IL-12) secretion
(Fig. 2k). IL-12 acts on proliferating CD4+ T-cells promoting their
differentiation into effector cells (Fig. 2l), the typical function of
which is IFN-γ secretion, a potent macrophage activator. The IFN-γ
signaling as well as the CD40-CD40L system also contributes to the
monocyte–macrophage maturation process (Fig. 2m) (Abbas et al.,
2000) and enhanced cytokine secretion by these cells.
The proposed model for the activation rate of naïve CD4+
T-cells in the LT compartment is presented in (5), where the
subscript act refers to activation. In this equation, stimulation
mediated by cell–cell interactions with macrophages (Fig. 2b) is
computed by the mass-action term (5a), whereas (5b) accounts for
the parcel due to immune interactions with infected CD4+ T-cells,
T
L
(Fig. 2n). In (5), the subscript τ in (5a) refers to a time delay
required for the antigen-stimulated naïve cell to complete its ﬁrst
mitotic cycle. For example, let NL¼NL(t) the LT naïve CD4 T-cell
population at time t. Thus, NLτ ¼NLðt−τÞ:
dNL
dt
 !
act
¼ −hcc PLτ þ f PP
L
τ
 
1þ βτ
 
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
ð5aÞ
þ TLτ|{z}
ð5bÞ
0
BB@
1
CCANLτ ¼−aτNLτ ð5Þ
where β¼ C
L
sC þ CL
 !
|ﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄ}
ð6aÞ
EL
EL0
 !
|ﬄﬄ{zﬄﬄ}
ð6bÞ
ð6Þ
[IL-2]
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the cell–cell-mediated stimulation of a naïve CD4+ T-cell depends
on the physical contact between it and an APC (Fig. 2b) (or infected
T-cell; Fig. 2n), which is assumed to occur at rate hcc. By applying
Smoluchowski's formula, we have hcc≤4.3410−4 mm3 day−1.
Here, HIV-infected macrophages, P
L
, are assumed to be less
efﬁcient than healthy macrophages, PL, to perform their APC
functions (Fig. 2b) and cytokine secretion (Fig. 2k) (Abbas et al.,
2000; Stites et al., 1994; Friedman et al., 2008). This is modeled by
introducing an efﬁciency coefﬁcient fP (fP∈[0, 1]) in (5a). On the
other hand, uninfected as well as infected long-lived cells, when
activated, are assumed to perform their immunological functions
with increased efﬁciency.
However, we do not discretize the APC pool into two distinct
subpopulations of resting and activated macrophages. Instead, a
continuous approach is adopted in which the homeostatic activity
of resting APCs – represented by the unitary constant in (5a) – is
preserved after macrophage activation and the increased perfor-
mance of the APC function associated to the activated state is
considered separately by a logistic function β, which is assumed to
be dependent on the IFN-γ concentration, C (Fig. 2c) (Friedman
et al., 2008) and on the stimulation level from the CD40-CD40L
system (Fig. 2d). Since the concentration of cytokines in the
extracellular medium can rise sharply during trauma or infection,
a saturation function is proposed to represent the IFN-γ stimula-
tion by effector CD4+ T-cells, EL, as in (6a). Hence, the macrophage
activation rate saturates for high IFN-γ concentrations, but it is
particularly downregulated when the cytokine availability
becomes smaller than a critical threshold, the IFN-γ half-saturation
concentration sC, which is required to provide macrophage activa-
tion (Fig. 3). Since IFN-γ stimulated immune cells are preferentially
recruited from the systemic circulation to the CNS compartment,
the same logistic function (6a) is considered in the cytokine-
dependent efﬁciency model for cellular transport (see Appendix A).
Similarly, the APC stimulation due to the CD40-CD40L system should
saturate at high T-cell concentrations. However, during the HIV
infection, the concentration of short-lived healthy CD4+ T-cells never
gets high compared to the number of long-lived cells, such as
macrophages. In fact, it has been estimated that there are approxi-
mately 1011 CD4+ T-cells and 109–1012 long-lived cells in a person
(Perelson and Nelson, 1999). Thus, we ignore saturation effects and
assume that the contribution of the CD40-CD40L system varies
linearly with the relative density of effector CD4+ T-cells in respect
to its homeostatic concentration, EL0 (Table B.1 of Appendix B), as
in (6b).
The CD4+ T-cells respond to the antigen presence through
cellular activation and proliferation as a result of autocrine/para-
crine IL-2 stimulation (Fig. 2p and q). However, if this proliferative
response is not regulated, each encounter with a foreign anti-
gen would lead to unending CD4+ T-cell expansion. The down-
regulation of CD4+ T-cell proliferation occurs by two highly
regulated and coordinated cellular death processes involving the
activation of cytosolic enzymes (Abbas et al., 2000; Badley et al.,
2000; Nguyen and Russell, 2001): (i) activation-induced cell death
(AICD) is a Fas ligand (FasL)-dependent apoptotic pathway that is
triggered by the binding of FasL to the death-inducing membrane
receptor Fas, also called CD95 or Apo-1. When mature T-cells are No macrophage stimulation by IFN-γ.
Above this point, IFN-γ stimulus tends to saturate; 
Below this point, IFN-γ stimulus decreases quickly.
[IFN-γ]
0
sC
Fig. 3. IFN-γ half-saturation concentration for macrophage activation.repeatedly stimulated by antigens and growth factors (e.g., IL-2),
they co-express Fas and FasL (Jenkins, 2003). The cross-linking of
Fas by FasL on the same cell or adjacent cells leads to activation of
caspases-8 and, ultimately, to apoptosis, and (ii) programmed (or
passive) cell death (PCD) is an important homeostatic mechanism
in the immune system, which results from the deprivation of
necessary survival stimuli, such as IL-2. This implies a rapid
increase in the permeability of mitochondrial membranes and
the release of several proteins that act as cofactors to ultimately
activate caspases-9, this mode initiating an apoptotic-signaling
pathway (Abbas et al., 2000). In order to represent such apoptotic
processes operating on lymphoid effector T-cells mass-action,
type-terms with logistic functions are proposed as follows:
AICD :
dEL
dt
 !
aicd
¼ −dfas
1þ XL
XL
 !
|ﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄ}
ð7aÞ
AL
smax þ AL
 !
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
ð7bÞ
EL ð7Þ
PCD :
dEL
dt
 !
pcd
¼−dd
1−X
L
X
L þ X
L
 !
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
ð8aÞ
smin
AL þ smin
 !
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
ð8bÞ
EL ð8Þ
Here, dfas and dd denote the maximum rates of T-cell deletion
mediated by Fas-induced signals (AICD) and passive death (PCD),
respectively. While there is no experimental evidence that the
CD4+ T-cell expansion is regulated by logistic terms such as (7a)
and (8a) above, some authors have suggested that density-
dependent controls may rule the population size of immune cells
in vivo (Perelson and Nelson, 1999). In fact, it has been shown that
during homeostasis-driven proliferation, T-cells stopped dividing
when the cellularity of the host lymphoid compartment was
restored (Goldrath et al., 2000). In this sense, since there is a
direct control over the exponential behavior of the CD4+ T-cell
proliferation process, the AICD mechanism efﬁciency is assumed to
rise non-linearly as the ratio between infected (X
L
) and healthy
(XL) cell subpopulations in the LT increases, as in (7a). Conversely,
from a major regulator mechanism for the uninfected state or
scenarios approaching this stationary condition, the PCD efﬁciency
is assumed to vary just linearly with the relative density of
infected cells, as in (8a).
The IL-2 signaling pathway is considered in (7b) and (8b)
(Fig. 4). In order to model saturation effects, the AICD mechanism
efﬁciency is assumed to be asymptotically enhanced when the IL-2
concentration in the LT, AL, overcomes a critical threshold smax, as
in (7b). Similarly, the logistic term (8b) is proposed to model the
PCD-mediated apoptosis approaching its maximum rate, dd, when-
ever the IL-2 availability falls below a minimum threshold smin.
As pointed out by Abbas et al. (2000), “it is intriguing that the
same cytokine (IL-2) can stimulate T-cell survival and proliferation
on the one hand, and promote cell death on the other”. Thus, we
speculate that there is an IL-2 concentration range, below which No death through AICD;    
 PCD at maximum rate. 
Above this point, AICD tends to saturate; 
Below this point, AICD is quickly inhibited.
0
i2max
i2min
Above this point, PCD approaches zero; 
Below this point, PCD is quickly enhanced. 
Fig. 4. IL-2 critical thresholds for effector CD4+ T-cell apoptotic routes.
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death is favored via AICD mechanism (Fig. 4).
Besides the chronic immunologic stimulus in HIV patients, HIV
infection may be unique in its ability to induce T-cell apoptosis
through a vast repertory of other speciﬁc mechanisms (Badley
et al., 2000). In fact, HIV-encoded proteins have been shown to
induce apoptosis of infected as well as of uninfected cells (Badley
et al., 2000). Here, two mechanisms of HIV-associated lymphocyte
apoptosis triggered by aberrant cellular activity mediated by
Fas-induced signals are considered: (iv) Env-CD4 cross-linking
mediated apoptosis (ENV), which is triggered by the cross-linking
between the viral glycoprotein gp120/gp41 (Env) and the CD4
molecule expressed on the cellular membrane of previously
activated CD4+ T-cells. By assumption, gp120 is expressed on
viable viral envelopes as well as on the cellular membrane of
HIV-infected cells. Since it does not require cell infection (Badley
et al., 2000), ENV competes with the cellular infection mechan-
isms (virus-to-cell and cell-to-cell) to promote cell susceptibility to
apoptosis at the time-scale of days (Badley et al., 2000), and (v)
Tat-induced apoptosis (TAT), the clinical relevance of which comes
from the fact that viral protein Tat is readily secreted by infected
cells and can induce apoptosis (Badley et al., 2000). We hypothe-
size that the ENV and TAT mechanisms operate only in mature
T-cells (i.e., memory or effector subpopulations), since the suscept-
ibility to the Fas-FasL system is developed after the proliferation
phase (Badley et al., 2000). The proposed models for HIV-speciﬁc
apoptotic pathways are stated by Eqs. (9) and (10) for the effector
subpopulation of the LT.
ENV :
dEL
dt
 !
env
¼−dfasðhccX
L þ hvcf vVLÞEL ð9Þ
TAT :
dEL
dt
 !
tat
¼−dfas
VL
sv þ VL
 !
EL ð10Þ
In (9), fv denotes the constant fraction of viable envelopes within
the viral population. As for the proposed cytokine-dependent
logistic models, we assume that Tat-mediated apoptotic pathway
may saturate when the Tat availability in the extracellular medium
is high. Since it is difﬁcult to estimate a half-saturation constant
for the Tat-secreting HIV-infected cell subpopulation, we assume
that the Tat production by infected cells is proportional to the viral
load in the considered compartment, as in (10).2.5. The cellular infection model
The newly synthesized naïve CD4+ T-cells are assumed to be
susceptible to infection but not to productive infection (Tang et al.,
1995). This is taken into account for the viral load balance, sinceFig. 5. The CD4+ T-celfree viral particles are permanently consumed in the cellular
infection process. On the other hand, memory CD4+ T-cells are
assumed to be susceptible to infection at post-integration level
(Essunger and Perelson, 1994) with continuous viral replication
(at rate nm virus cell−1), albeit in a lower level than that observed
for productive infection of activated (effector) CD4+ T-cells
(ne virus cell−1).
One determining factor of the virus-to-cell infection efﬁciency
is the concentration of free viral particles in the neighborhood of
the target cell (Carr et al., 1999). This HIV could emerge from two
main sources (Grossman et al., 1998). Firstly, it could be produced
at a distance by CD4+ T cells recently infected. This long-range
transmission may well be dominant when viral burdens are high.
Alternatively, the infectious agent may emerge locally, coupled
with an immunologic interaction with an APC that results in T-cell
activation. This proximal activation and transmission form may be
particularly important when viral burdens are low. Hence, while
chronically and latently infected cells may not contribute signiﬁ-
cantly to the viral load, they may be instrumental in sustaining the
infection (Grossman et al., 1998).
Moreover, due to their location and APC function, macrophages
may be of central importance for the local cell-to-cell transmission
of virus, especially in the LT compartment that is the major site of
HIV replication in vivo (Dybul et al., 2003). In this sense, two
infection mechanisms namely virus-to-cell (long-range transmis-
sion) and cell-to-cell (proximal activation and transmission) (Carr
et al., 1999; Luce et al., 1993) are considered in the proposed model
(Fig. 5).
As in Perelson and Nelson (1999), the virus-to-cell infection
(VTC) (Fig. 5a) is represented by a mass-action model:
VTC :
dEL
dt
 !
vtc
¼ −kevcELVL ð11Þ
with kevc being the time-dependent infection rate of effector CD4+
T-cells by free HIV as function of the: (a) rate of collision between
cells and virions (hvc), (b) ratio of viable to defective virions (fv)
and (c) CXCR4 and CCR5 regulation and expression patterns on the
target cell according to its type and phenotypic characterization, as
proposed by Joly and Pinto (2005):
kevc ¼ f vhvcðvR5IER5 þ vR5X4IER5X4 þ vX4IEX4Þ ð12Þ
In (12), vi (i¼R5, R5X4, X4) is the normalized fraction of R5,
R5X4 and X4 viral subpopulations at time t whereas IEi is a
normalized measure of the susceptibility of effector CD4+ T-cells
to infection by the viral isolate i as a function of the CD4, CXCR4
and CCR5 expression patterns on the cell surface.
Cell-to-cell contact among immune effector cells and the
resultant high levels of proinﬂammatory cytokines produced in
the LT compartment favor HIV replication in several ways (Dybul
et al., 2003). HIV infection spread by cell–cell contact betweenl infection model.
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as the virus-to-cell one (Mandarelli et al., 1995), and an important,
if not the major, HIV infectious route in-vivo (Carr et al., 1999).
Here, cell-to-cell transmission is assumed to occur from chroni-
cally infected macrophages or productively and latently infected
CD4+ T-cells to healthy T-cells (Table 1). Regarding the viral
homogeneity in R5 strains typically observed during the primary
HIV infection, cell–cell fusion (CCF) and syncytia formation invol-
ving CD4+ T-cells is not expected early in the course of infection,
except in the case of HIV intravenous transmission when CXCR4-
using viral strains may be directly introduced in the host (Davis
et al., 1997). Polarized secretion of viral envelopes (PSVE) (Pearce-
Pratt et al., 1994) and intracellular viral stock transfer (IVST) (Carr
et al., 1999) are assumed to be mediated by NSI HIV and produce
two infected cells. The proposed models for representing the cell-
to-cell infection mechanisms are based on mass-action processes,
as in (13)–(15).
Since the naïve CD4+ T-cell pool is susceptible to infection at
the preintegration level, no expression of viral proteins on the cell
surface is expected. Thus, the CCF mechanism is assumed to be
mediated solely by HIV-infected memory (M) or effector (E) CD4+
T-cells. This is modeled in (13), where kecc is the infection rate
model of the target cell (EL), as in (14) (Joly and Pinto, 2005).
CCF :
dEL
dt
 !
ccf
¼−keccf SIðE
L þMLÞEL ð13Þ
kecc ¼ hccðvR5IER5 þ vR5X4IER5X4 þ vX4IEX4Þ ð14Þ
Similarly, the infection of lymphoid CD4+ T-cells mediated by
PSVE mechanism is stated in (15). Here, SI isolates are not involved
and only productively infected CD4+ T-cells, which are able to
secrete a sufﬁcient number of viral particles locally in the region of
the cell–cell contact with the target cell, are assumed to be the
infectious entity.
PSVE :
dEL
dt
 !
psve
¼−keccð1−f SIÞE
L
EL ð15Þ
Lastly, the immune interaction between healthy effector CD4+
T-cells and infected macrophages (P
L
) through the ISVT mechan-
ism is considered in (16). In contrast to CD4+ T-cells, macrophages
are not susceptible to syncytia formation even when the latently
infected long-lived cell shelters CXCR4-using isolates, since an
infected APC remains structurally intact and functionally compe-
tent by hypothesis.
ISVT :
dEL
dt
 !
isvt
¼ −keccPLEL ð16Þ
2.6. The cellular proliferation model
The factors that determine whether a progeny of antigen-
stimulated naïve CD4+ T-cells will become phenotypically aTable 1
Cell-to-cell infection mechanisms.
Mechanism From (infected cell) To (susceptible
Cell–cell fusion (CCF) (Davis et al., 1997) Effector/memory
CD4+
T-cell
Any CD4+ T-cell
Polarized secretion of viral envelopes (PSVE)
(Pearce-Pratt et al., 1994)
Effector CD4+ T-cell Any CD4+ T-cell
Intracellular viral stock transference (IVST)
(Carr et al., 1999)
Macrophages Any CD4+ T-cellshort-lived effector or long-lived memory cell remain poorly
understood (Abbas et al., 2000; Tough and Sprent, 2003).
Part of the uncertainty may stem from the fact that memory
CD4+ T-cells are heterogeneous, being broadly divisible into
“central” memory and “effector” memory subpopulations, which
might be produced by different pathways (Tough and Sprent,
2003). Central memory cells may arise under suboptimal stimula-
tion conditions, that is, when antigen or polarizing cytokines, or
both, are present only in low concentrations; this setting may exist
late in the immune response, when much of the antigen has been
eliminated and APCs are exhausted in terms of their ability to
secret cytokines (Fig. 2l). On the other hand, the generation of
effector memory cells may require a higher level of stimulation.
Although this scenario is speculative (Tough and Sprent, 2003), it
implies that central and effector memory cells may arise from
distinct subpopulation of activated cells: central memory cells that
are an early intermediate in the differentiation pathway and
effector memory cells that arise from full-ﬂedged effector cells
late in response.
In this sense, two major mechanisms for the concomitant
generation of effector and memory CD4+ T-cells during an immune
response could be envisaged (Fig. 6; schemes a–c) (Jenkins, 2003;
Tough and Sprent, 2003; Farber and Cell Memory, 2000). The ﬁrst
one is composed by linear models, which neglect the heterogeneity
of the CD4+ T-cell population and assume that the memory pool is
due to partial reversion of effector cells into the memory pheno-
type at rate, kr (Fig. 6d). In the divergent models, memory and
effector CD4+ T-cells are generated directly (and exclusively) after
the clonal expansion of antigen-stimulated naïve CD4+ T-cells
(Farber, 2000) (Fig. 6b and c). Also, it has been shown that memory
CD4+ T-cells upon speciﬁc stimulation can proliferate and differ-
entiate into effector cells (Fig. 6e) (Abbas et al., 2000). Finally, as in
Essunger and Perelson (1994), we assume that infected CD4 T-cells
do not proliferate.
In the proposed model of Fig. 6, φ is the normalized fraction of
the naïve CD4+ T-cell pool that will differentiate into effector cells
after clonal expansion (Fig. 6b), whereas the complementary
fraction (1−φ) accounts for new memory cells (Fig. 6c) produced
under homeostatic conditions (uninfected state). Underscored by
in vitro observations, this process is assumed to be further
regulated by the antigenic stimulation level, since effector CD4+
T-cells emerge from proliferating cells that received more signal-
ing through T-cell receptors than the bulk of the responding
population (Tough and Sprent, 2003). Moreover, such effector
CD4+ T-cell pool is subject to an additional differentiation process,
as a consequence of priming, into cells that mainly produce IL-2
and IFN-γ (TH1) or cells that are very effective in helping precursors
of antibody-secreting cells (TH2). Here, we assume that IL-12 is the
major driving force to induce TH1 differentiation (Fig. 2l) (Abbas
et al., 2000).
While antigenic recognition and recruitment are processes
admitted to occur in the PB compartment (Section 2.1), the naïve
CD4+ T-cell activation, proliferation and differentiation into effec-
tor or memory cells are assumed to be processes exclusivelycell) Final state Activity
Multinucleated giant infected cells (syncytia) After the emergence
of SI isolates
Individual infected cells Entire course of the
infection
Individual productively infected cells Entire course of the infection
Full differentiation into helper or 
memory CD4 T-cell 
Remaining (mN - 1) mitotic cycles of proliferating activated CD4 
T-cell (high IL-2Rβγc; low to high IL-2Rα; IL-2 synthesis) 
Antigen presentation to the 
resting CD4 T-cell  
First mitotic cycle of 
antigen-stimulated naïve 
CD4 T-cell (low IL-
2Rβγc; absent IL-2Rα)
tt2t3t4t)1m(t N ... ηηηηη −−−−−−
η)2m(t N −−
RESTING EFFECTOR 
τ η
Fig. 7. The CD4+ T-cell proliferation model.
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Fig. 6. The activation, proliferation and differentiation model for CD4+ T-cells.
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(Romanyukha and Yashin, 2003), where macrophages reside in
large scale. Mathematical modeling for naïve T-cell activation is
detailed as follows. The corresponding model for memory CD4+
T-cell reactivation (Fig. 6e) is analogous, but it is assumed that a
lower level of the growth factor (IL-2) is required, since antigen-
stimulated T-cells are more responsive to IL-2 than naïve T-cells
(Abbas et al., 2000). Moreover, full differentiation into effector
cells (i.e., φ¼1) is considered because memory cells do not
proliferate to renew themselves (Jenkins, 2003).
Naïve CD4+ T-cells shown signs of DNA replication and cell
division as early as 48 h after exposure to antigen in vivo (Jenkins,
2003), whereas the subsequent divisions (5–10 mitotic cycles
(Murray et al., 1998)) occur intermittently at shorter time periods
each (Abbas et al., 2000). As others (Perelson and Nelson, 1999),
we admit that T-cell proliferation tends to shut off whenever the
lymphoid CD4+ T-cell count approaches a saturation condition.
Similarly, we hypothesize that the persistence of memory CD4+
T-cells may occur in the absence of antigen and is related to a
“space-ﬁlling” homeostatic proliferation (Jenkins, 2003). Here,
such a control is performed by varying the number of mitotic
cycles performed by the antigen-stimulated naïve (or memory)
CD4+ T-cell according to a density-dependent integer function, as
in (17). In this equation, mN0 denotes an upper bound for mN, the
number of mitotic cycles performed by proliferating CD4+ T-cells
(originated from antigen-stimulated naïve cells) at time t, TL is the
concentration of the CD4+ T-cell subpopulation (any phenotype) in
the LT compartment at time t, and sT is its corresponding half-
saturation constant.
mN ¼ round mN0 1−
TL
sT þ TL
 ! !
ð17ÞThe action of IL-2 on CD4+ T-cells is mediated by binding to two
major IL-2 receptor proteins namely IL-2Rα and IL-2Rβ. IL-2Rα
appears upon antigen receptor-mediated T-cell activation and
binds IL-2 with a half-saturation concentration sα of approximately
10−8 M. Differently, IL-2Rβ is already expressed in naïve CD4+
T-cells and forms a complex with a polypeptide called common γ
(γc) chain designed IL-2Rβγc; its afﬁnity of binding with IL-2 is
higher than to IL-2Rα, with corresponding half-saturation constant
sγ of about 10−9 M. IL-2Rα forms a complex with IL-2Rβγc increas-
ing the afﬁnity of the signaling receptor for IL-2, thus allowing a
growth signal to be delivered at signiﬁcantly lower cytokine
concentrations. As a result, activated CD4+ T-cells, which express
both IL-2Rα and IL-2Rβγc (Fig. 7), can bind IL-2 much more tightly
(sαγ≅10−11 M) (Abbas et al., 2000).
By hypothesis, antigen stimulated naïve CD4+ T-cells remain
phenotypically characterized as resting during the ﬁrst mitotic
cycle (Fig. 7). Once the ﬁrst mitosis is concluded, the two new
daughter cells become proliferating effector CD4+ T-cells able to
perform their immunological functions.
By modeling the CD4+ T-cell expansion stages, one can perform
a detailed sensitivity analysis of the disease dynamics early in the
infection course, when a number of interrelated events with time
scale ranging from hours to days take place. Detailed modeling
concerning the dynamics of initial HIV spread in the body has been
a subject of investigation by some HIV modelers in recent years
(e.g., Wendelsdorf et al., 2011), since a better understanding of the
host inﬂammatory response subsequently to exposure to HIV is a
necessary component that vaccines and early interventions seek to
exploit. Such theoretical analysis may be of great interest, since
experimental data regarding the early immune response to HIV
upon viral exposure in humans is difﬁcult to obtain as it requires
invasive tissue biopsies taken from host tissues within a very short
time period post-infection. However, meeting these goals requires
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do not try to formulate a model that can capture all the features of
the adaptive immune response or all host and viral factors, but
rather a model that can represent many salient features of the CD4
+ T-cell system along the proliferation process for which some
parameters can be plausibly estimated based on the sparse data
available. Regarding (5), antigen-stimulated naïve CD4+ T-cells at
time t−τ will produce:
2
dNLτ
dt
 !
act
ALτ
sγ þ ALτ
 !
¼ 2aτNLτ
ALτ
sγ þ ALτ
 !
|ﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄ}
ð18aÞ
ð18Þ
effector CD4+ T-cells at time t. In (18), the constant 2 accounts for
the ﬁrst mitotic cycle. By assumption, the growth of proliferating
T-cells is regulated by the cytokine availability at the beginning of
each mitotic cycle. Hence, a naïve CD4+ T-cell pool subject to
antigenic stimulation will proliferate with half-maximal growth
stimulation occurring at the same concentration of IL-2 that
produces half-maximal binding to IL-2Rβγc. In this sense, the
logistic term (18a) is proposed, in which sγ denotes the IL-2 half-
saturation concentration for the ﬁrst mitotic cycle of IL-2Rβγc-
expressing naïve CD4+ T-cells. The subscript τ in Aτ is a model
parameter that denotes a time delay of in τ days in the variable A.
Mathematically, Aτ(t)¼A(t−τ), for any time t. Analogously, time
parameters η and ω in the subscript denote, thereafter in this
paper, a corresponding time delay in the associated state variable.
Similarly, those naïve CD4+ T-cells that were stimulated at time
t−τ−η will produce:
22aτþηNLτþη
ALτþη
sγ þ ALτþη
 !
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
ð19aÞ
ALη
sαγ þ ALη
 !
|ﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄ}
ð19bÞ
ð19Þ
effector CD4+ T-cells at time t. In (19), the factor 22 accounts for
the clonal expansion following the ﬁrst two mitotic cycles. Anti-
genic and IL-2-mediated stimulations related to the ﬁrst mitotic
cycle are represented by the term (19a), which is Eq. (18) delayed
in η time units. The second mitotic cycle initiates at time t−η and
has growth rate regulated by a relatively low IL-2 half-saturation
concentration, since upon activation, IL-2Rα was rapidly expressed,
thereby reducing the concentration of IL-2 needed for growth
stimulation. Since strongly activated, these effector CD4+ T-cells
under clonal expansion are admitted do not return to the memory
phenotype until all the mN mitotic cycles are completed, as
illustrated in Fig. 6d. In addition, we hypothesize that the overall
proliferation process is performed within the LT compartment
before releasing effector CD4+ T-cells to the systemic circulation.
For the third mitotic cycle related to those cells that have left the
resting pool at time t−2η (i.e., antigen-stimulated cells at time
t−τ−2η), (20) arises:
23aτþ2ηN
L
τþ2η
ALτþ2η
sγþALτþ2η
 
AL2η
sαγþAL2η
 
ALη
sαγþALη
 
OR
23aτþ2ηN
L
τþ2η
ALτþ2η
sγ þ ALτþ2η
 !
∏
2
j ¼ 1
ALjη
sαγ þ ALjη
 !
ð20Þ
Generalizing for those cells ﬁrst stimulated at time t−τ+(mN−1)
η (i.e., the older cluster of proliferating effector CD4+ T-cells at time
t), the cellular population that will conclude the proliferation
phase at time t is given by (21):
2mNaτþðmN−1ÞηN
L
τþðmN−1Þη
ALτþðmN−1Þη
sγ þ ALτþðmN−1Þη
 !
∏
mN−1ð Þ
j ¼ 1
ALjη
sαγ þ ALjη
 !
ð21ÞHence, for a given time t, the proliferating T-cell population due
to the activation of naïve CD4+ T-cells results in
∑
mN
i ¼ 1
φi2
iaτþði−1ÞηN
L
τþði−1Þη
ALτþði−1Þη
sγ þ ALτþði−1Þη
 !
f Ni
 !
ð22Þ
with
f Ni ¼
1 if i¼ 1
∏
i−1
j ¼ 1
ALjη
sαγ þ ALjη
 !
otherwise
8><
>: ð23Þ
and
φi ¼
1 if iomN
BLη
sBþBLη
 
otherwise
8><
>: ð24Þ
where φ is the proposed logistic function for regulating the CD4+
T-cell differentiation process (Fig. 6b and c). According to this
model, the rate of differentiation into the effector phenotype is
dependent upon the IL-12 availability in the LT compartment
(Fig. 2l) and may saturate for high cytokine concentrations. In
(24), a time delay η is considered since the differentiation process
is assumed to be a function of the cytokine concentration at the
beginning of the last mitotic cycle.
The resulting model for the effector CD4+ T-cell balance in the
LT compartment is stated by (25).
dEL
dt
¼ dE
L
dt
 !
pro
−
dEL
dt
 !
apo
−
dEL
dt
 !
inf
−
dEL
dt
 !
rev
−
dEL
dt
 !
rec
ð25Þ
Here, the positive term identiﬁed by the subscript pro accounts
for the increase in the effector CD4+ T-cell population due to the
cellular proliferation. This parcel computes proliferating T-cells
deriving from the antigen-stimulated naïve cells as well as from
the reactivation of memory cells. The negative terms account for
homeostatic and HIV-associated apoptotic mechanisms (apo),
which are modeled as in (7)–(10), and HIV infection (inf) of effector
CD4+ T-cells according to Eqs. (11), (13), (15) and (16). Finally, two
additional biological mechanisms are considered:
(vi) Reversion to the memory state: It is admitted that effector
CD4+ T-cells revert to the resting (memory) phenotype at constant
rate kr (Fig. 6d):
dEL
dt
 !
rev
¼ krEL ð26Þ
(vii) Recruitment to the PB compartment: Conversely from the
case of memory cells, for which blood-to-lymph recirculation is
hypothesized (Abbas et al., 2000; Tough and Sprent, 2003), active
transport of effector cells from the LT to the PB compartment is
here considered through a density-dependent function aiming at
preserving homeostatic conditions related to the PB effector cell
count. This is modeled in (27), where rP denotes the maximum
recruitment rate and EP is the dynamic concentration of effector
CD4+ T-cells in the blood, whose corresponding half-saturation
concentration is sE.
dEL
dt
 !
rec
¼ rP 1− E
P
sE þ EP
 !
EL ð27Þ
2.7. The viral load model
The LT compartment has a volume vL and processes fb liters of
blood per day by removing viral particles and HIV-infected cells
according to a process whose efﬁciency is dictated by the FDC
network integrity (θ) (Fig. 8).
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term (28b) accounts for virions that enter the LT compartment by
convective transport whereas (28b) is related to the viral load
escape from the lymphoid tissues to the bloodstream due to the
impairment of the FDC network integrity (θ) caused by SI HIV.
The dichotomy in viral load between these compartments dictatesFree HIV from PB 
Escape to PB
V L
CjCˆ
nj
dv
kjvc
FDC
death
bindingproduction
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Fig. 8. The HIV model for the LT compartment.
0 100 200 300 400 500
0
1
2
3
4
5
x 107
Days after host initial infection
H
IV
 R
N
A
 le
ve
l
CNS
PB
LT x 0.1
CD
4 
T-
ce
ll 
co
un
t
0 100 200 300 400 500
0
200
400
600
Days after host initial infection
Ce
ll 
co
un
t
Infected macrophages (LT) x 0.1
Monocytes (PB)
Macrophages (CNS)
Infected macrophages (CNS)
IL
-2
 c
on
ce
nt
ra
tio
n
0 20 40 60 80 100
0
1
2
3
4
5 x 10
7
Days after host initial infection
H
IV
 R
N
A
 le
ve
l
Base case
Modified Tau
LT
 in
fe
ct
ed
 m
em
or
y
Fig. 9. (a)–(d) The natural history of HIV infection (base case): (a) viral load (RNA copies/m
mm3). CNS values103 and LT values10−2; (c) monocyte–macrophage cell lineage c
(pg mm−3). CNS values106 and PB values103; (e) plasma viral load dynamics (cop
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The probability that an infected cell will die as a function of
time or cell age is not known. Hence, we made the simplest
possible assumption, that is, that the rate of virus production per
infected cell of type j is a constant nj, as in (28c). However, after
HIV infection, the viral intracellular life cycle initiates and a time
delay ε representing the so called “eclipse phase” between initial
infection of the cell and the start of the virus production should be
considered (Nelson et al., 2000). Here, C
LT
jε
is the concentration of
the infected cell type j at time t−ε in the LT compartment.
Since high viral loads typically observed during the acute phase
of infection can dramatically raise the probability of encounter and
binding of free viral particles on the surface of immune cells, the
loss of virus due to infection of a cell is explicitly considered (28d).0 100 200 300 400 500
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l; one virion has 2 RNA strands). LT values10−1; (b) total CD4+ T-cell count (cells/
ount (cells/mm3). LT values (infected macrophages)10−1; (d) IL-2 concentration
ies/ml) associated to a 33% reduction in the duration of the ﬁrst mitotic cycle (τ)
pulation dynamics associated to a 33% reduction in the IL-2 concentration threshold
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clearance mechanism (Perelson and Nelson, 1999), which should
also consider that viral particles are subject to natural death at rate
dv, as in (28e). Each time a cell is infected, at least one virion must
enter, and thus one could add the term –kjvcVCj to the virus
balance, where kjvc is the virus-to-cell infection rate of an immune
cell of type j (Cj) (Joly and Pinto, 2005). By assumption, infection
mechanisms mediated by cell–cell contact (CCF, PSVE and IVST) do
not require free viral particles to occur.3. Results
The full model has 32 state variables and differential equations
(Appendix A), and 56 parameters (Appendix B). Three additional
time-dependent parameters, vR5, vR5X4 and vX4, deﬁne the dynamics
of R5, R5X4 and X4 viral phenotypes throughout the infection
course according to Joly and Pinto (2006). As in Tuckwell and
Le Corfec (1998), the model parameterization presented in
Appendix B, thereafter in this paper referred as base case, relied
either on the current best available references or on estimated
values that are based on: (a) either the order of magnitude of the
parameter or qualitative information from literature, as in Essunger
and Perelson (1994), and/or (b) the order of magnitude of the
variable with which the parameter is correlated, as in Sud et al.
(2006), and/or (c) the steady-state behavior of the immune system
for the uninfected state, as in Murray et al. (1998). Some of the
model parameters are strongly interrelated and may be scaled in
combination, without affecting the dynamics of the model.
The resulting DAE system was solved with an explicit Runge–
Kutta (4) and (5) pair of Dormand and Prince that uses a free
interpolant of order 4 implemented in the MATLABs routine library
(Shampine and Reichelt, 1997) to obtain temporal dynamics for each
element of the model. For the base case instance, major model state
variable proﬁles are depicted in Fig. 9 for each anatomic compartment.
Also in this ﬁgure, graphs (e) and (f) depict some simple sensitivity
analysis of key model parameters associated to the proposedmodeling
for expansion stages early in the infection course. Such parametric
variations could mimic the patient-speciﬁc genotypic background.
Five case studies were designed in order to theoretically
evaluate the immune system dynamics and clinical monitoring
parameters (viral load and total CD4+ T-cell count in plasma) in
response to continuous and intermittent IL-2 therapy, as follows.
3.1. Case study 1: IL-2 therapy early in the infection course
A realistic scenario in which the host initial infection is
triggered by the arrival of few, say 10, HIV-infected APCs from
mucosal tissues into the paracortical regions of draining lymph
nodes is considered. Initially, the viral population is phenotypically
homogeneous in R5 isolates, that is, vR5(t¼0)¼1 and vR5X4(0)¼
vX4(0)¼0. SI viral isolates are assumed to emerge 1 year after
initial exposure to HIV according to the NSI-SI evolution model
from Joly and Pinto (2006). Model initial conditions and para-
meterization are summarized in Appendix B.
Continued and intermittent courses of IL-2 administered intra-
venously were considered (Table 2). Simulated proﬁles for clinical
monitoring parameters (HIV RNA level and total CD4+ T-cell
counts in plasma) and major model state variables in response
to continued IL-2 therapy are shown in Figs. 10 and 11. Due to
mathematical standpoints, a smooth function with area under the
curve (AUC) equivalent to the speciﬁed IL-2 daily dosage was
considered to represent the infusion dynamics during an IL-2
therapy cycle. In all cases, therapies are initiated right after
seroconversion of the host, which is assumed to occur 10 days
after exposure to HIV.Additional simulations were performed by hypothesizing that
both IL-2 binding and growth stimulation can be blocked by
antibodies to IL-2Rα and IL-2Rβγc, and most efﬁciently by a
combination of antibodies to multiple receptor subunits (Abbas
et al., 2000), since in vitro studies have demonstrated that soluble
receptors can compete with their corresponding cell surface
receptors thereby serving negative regulatory roles. In fact, among
the major questions related to these soluble receptors is (Leonard
2003): “do they have therapeutic applications?”.
The role of soluble forms of IL-2 cytokine receptors on the
dynamics of key clinical monitoring parameters (HIV RNA and
CD4+ T-cell counts in plasma) was evaluated by quantifying the
impact of distinct regimens of continued infusion of soluble
IL-2Rα. Here, IL-2Rα is assumed to compete with cell surface
receptors by binding to IL-2. Simulated results regarding IL-2Rα
therapy initiation after seroconversion (10 days after exposure to
HIV) for three distinct levels of IL-2 inhibition (20%, 80% and 90%)
are depicted in Fig. 12.3.2. Case study 2: Role of artiﬁcial IL-2 stimulation in the long-term
Computation experiments in the long-term were ﬁrstly per-
formed regarding the assumption that, under atypical high levels of
IL-2 (such as that produced by immunotherapy), the expression of
IL-2 receptors on the cell surface is reduced thereby changing the
IL-2 half-saturation concentration set-points that regulate CD4+
T-cell growth as well as apoptotic mechanisms (sγ, sαγ, smin and smax).
The logistic model (29) was considered, in which the IL-2 half-
saturation constants are altered (increased) as the relative gap
between the lymphoid IL-2 concentration, AL, and its corresponding
homeostatic value, ALss, increases. In (29), the dynamic set of IL-2
half-saturation parameters is identiﬁed by superscript “s”:
ssi ¼ sið1þ ððAL−ALssÞ=ALssÞÞ; i¼ α; β; min;max ð29Þ
Clearly, at the uninfected state, we have that ALss¼AL(Table B.1)
and ssi ¼ si, i∈{γ, αγ, min, max} (Table B.2). Simulated proﬁles for the
viral and lymphocyte dynamics in the LT compartment regarding
scheme I3 (Table 2) for the long-term management of HIV
infection are shown in Fig. 13. In this ﬁgure, a sexually infected
host initiating IL-2 therapy right after seroconversion is consid-
ered. By assuming that the host exposure to HIV occurs at day 0,
seroconversion is admitted at day 10 and the emergence of SI viral
isolates at day 365. In Fig. 13, the baseline proﬁles consider the IL-2
saturation coefﬁcients from Table B.2 whereas the modiﬁed model
relies on Eq. (29). As can be seen, by representing the shedding of
IL-2R in the proposed model, the immune degradation in the long-
term becomes something more accentuated (graph (c)). Since a
lower viral load pattern is obtained (graph (b)), one can infer that
mechanisms other than the viral cytopathicity are acting to
deplete the CD4+ T-cell pool.
However, the model shows a lack of adherence to the in vivo
behavior, since multiple studies have shown that intermittent IL-2
administration in long-term can lead to a signiﬁcant, selective and
sustained CD4+ T-cell expansion in vivo (Kovacs et al., 1995, 1996;
Dybul et al., 2003; De Paoli, 2001; Levy et al., 2003; Sereti et al.,
2007; Read et al., 2008; INSIGHT-ESPIRIT, 2009). In fact, labeling
studies have suggested that, although intense proliferation occurs
during the IL-2 administration as indeed reproduced by our
simulations (data not shown), the sustained CD4+ T-cell expansion
following an IL-2 cycle may result from the decreased turnover
and improved survival of naïve and central memory CD4+ T-cells
(Sereti et al., 2007; Read et al., 2008). In this sense, we reformulate
the model by considering dynamic death rates for the naïve and
memory CD4+ T-cell subpopulations according to an IL-2-density
Table 2
IL-2 regimensa.
Scheme Regimen : Dosage
Control No therapy
C1 Continuous : 1 MIUs a day
C2 Continuous : 8 MIUs a day
C3 Continuous : 16 MIUs a day
I1 Intermittent : 8 MIUs a day for cycles of 2 consecutive days each, administered at 2-day intervals
I2 Intermittent : 8 MIUs a day for cycles of 2 consecutive days each, administered every week
I3 Intermittent : 15 MIUs a day for cycles of 5 consecutive days each, administered at 8-week intervals for the 3 ﬁrst cycles. Additional cycles included reductions
of the IL-2 dose in decrements of 3 MIU a day per cycle until the minimum dose of 3 MIUs a day (INSIGHT-ESPIRIT, 2009)
a 103 U of IL-2 correspond to 0.33 μg of IL-2 (Niwa et al., 1991).
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Fig. 10. Impact of continued IL-2 therapy (schemes C1–C3) on the PB (a) and LT (b) IL-2 concentration, and on the HIV RNA level (RNA copies/ml) (c) and total PB CD4+ T-cell
count (cells/mm³) (d).
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dsjðtÞ ¼
dj if A
Pðt0Þosr for t−Ωot0ot
dj=F otherwise
j¼N;M
(
ð30Þ
Eq. (30) introduces two distinct states into the model. The ﬁrst
one aims to represent physiologic conditions, in which unusual
high IL-2 levels are not expected and, hence, the ‘corrected’ death
rate of a cell of type j at time t, dsj(t), must be identical to its
homeostatic value, dj (Table B.2 – Appendix B). The second state,
which is related to situations characterized by artiﬁcially elevated
levels of circulating IL-2 (e.g., immunotherapy), the homeostatic
death rate is decreased by a factor F. Once reduced to dj/F,
the death rate remains unchanged during Ω days before returning
to its homeostatic value dj. In (30), sr denotes the critical IL-2
concentration at which the decreased turnover and improved
survival condition for naïve and memory CD4+ T-cells are
triggered.
Again, simulation experiments based on (30) regarding distinct
combinations for (sr, F, Ω) did not reproduce an expected CD4+
T-cell expansion above baseline after each IL-2 cycle.
In order to examine the hypothesis that the obligatory function
of IL-2 may not be a growth factor for effector CD4+ T-cells, but a
controller of T-cells by potentiating apoptotic death of activatedCD4+ T-cells by the Fas pathway (Abbas et al., 2000), Eq. (31) was
proposed. Under atypical levels of IL-2 stimulation, biological
changes in the T-cell pool may arise (Sereti et al., 2007), including
not only changes in the CD4+ CD25+ T-cell survival (Read et al.,
2008), but also modiﬁcations in the rate of Fas-mediated apoptotic
processes (dfas). Since the FasL expression is induced by CD4+ T-cell
activation, (31) differs from (31) in the sense that the cell death
rate should be increased instead of reduced whenever the IL-2
availability overcomes a critical threshold sr.
dsf asðtÞ ¼
dfas if A
Pðt0Þosr for t−Ωot0ot
df asF otherwise
(
ð31Þ
Resulting proﬁles for viral and lymphocyte dynamics through-
out the infection course regarding intermittent IL-2 therapy
(scheme I3) and Eq. (31) are illustrated in Fig. 14 for distinct
parameterizations of the tuple (F, sr, Ω). In all the cases, SI isolates
are assumed to emerge 1 year after initial infection by the mucosal
route.
3.3. Case study 3: IL-2 therapy combined with HAART
Administration of highly active antiretroviral therapy (HAART)
combining different drugs, usually HIV reverse transcriptase and
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Fig. 11. Impact of continued IL-2 therapy (schemes C1–C3) on the dynamics of naïve (a), healthy memory (b), infected memory (c) and infected effector (d) CD4+ T-cells in
the PB. Cell counts in cells/mm³.
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M. Joly, D. Odloak / Journal of Theoretical Biology 335 (2013) 57–78 69protease inhibitors, has been successful in decreasing plasma
viraemia to extremely low levels in a substantial proportion of
HIV-infected patients (Dybul et al., 2003). In this section, we
analyze the effects of IL-2 therapy combined with HAART in
immune restoration. For the sake of simplicity, we do not differ-
entiate between reverse transcriptase and protease inhibitors.
Instead, we assume that HAART simply blocks the production of
new virions by HIV-infected cells. Since drug chemotherapy is not
100% effective (Perelson and Nelson, 1999), HAART activity is
modeled by reducing nj, the virus production rate by a HIV-
infected cell of type j, by a factor fp∈[0, 1].
Computational results focusing on the primary HIV infection
dynamics are considered in Table 3 and Fig. 15. In Table 3,
scenarios regarding a HAART effectiveness ranging from 25% to
99.5% and a host infected with HIV via mucosal route initiating
combined therapy (HAART plus IL-2 therapy (16 MIUs per day;
regimen C7)) right after seroconversion are considered. Fig. 15
illustrates the proﬁles for viral and lymphocyte dynamics asso-
ciated with HAART alone and HAART+IL-2 combined therapy early
in the infection course. By hypothesizing that the increase in the
Fas-mediated apoptosis rate is proportional to the increase in the
FasL expression on the cell, we have assumed F in the interval
(Kovacs et al., 1995; Dybul et al., 2003) in our simulation experi-
ments. These estimates are based on Nguyen and Russell (2001),which showed that cells treated IL-2 expressed 1.5 times the level
of FasL as T-cells deprived of IL-2.
In Fig. 16, virological and lymphocyte changes in plasma due to
HAART alone and HAART plus intermittent IL-2 therapy are
compared in the long-term. The corresponding dynamics of the
cell subpopulations in each anatomic compartment are summar-
ized in Table 4. In all cases, therapeutic schemes are initiated right
after seroconversion and SI isolates are assumed to emerge one
year after mucosal exposure to HIV. Also, Eq. (31) is considered
with Ω¼45 days, F¼2 and sr¼50 pg/mm³.
3.4. Case study 4: Intravenous infection with CXCR4-using isolates
Inoculation of a recipient with HIV-infected blood or blood
products is the second most frequent mode of HIV transmission
(Abbas et al., 2000). In this case, CXCR4-using isolates may be
introduced directly into the systemic circulation of the recipient
host. Here, intravenous infection mediated by 100 ml of HIV-
infected blood with 10,000 RNA copies/ml from a typical patient
with clinical AIDS is considered. In this new baseline, the initial
viral population is composed by 40% of R5X4 and 20% of X4, and
the viral phenotypic evolution is based on Joly and Pinto (2006)
(Fig. 17a). The resulting viral and lymphocyte changes in response
to immunotherapy combined with HAART (treatment initiated
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M. Joly, D. Odloak / Journal of Theoretical Biology 335 (2013) 57–7870right after seroconversion ) are presented in Fig. 17b and c. Fig. 17d
depicts the IL-2 concentration proﬁles in the LT for the baseline
(intravenous infection and no therapy) and the base case (mucosal
infection and no therapy).3.5. Case study 5: IL-2 therapy and immunosenescence
Effective immune defense in late age may be based on combined
slowing down of the several age-depending decay processes in the
M. Joly, D. Odloak / Journal of Theoretical Biology 335 (2013) 57–78 71immune system (Friedman et al., 2008; Romanyukha and Yashin,
2003). Most signiﬁcant shifts include (Romanyukha and Yashin,
2003): (a) thymus involution and reduction of the naïve CD4+ T-
cell production rate; (b) decline in the volume of the intact peripheral
lymphoid tissue, and (c) telomere loss in the process of self-
reproduction. Telomeres are the end parts of the chromosomes,
which become shorter at each cell division. A CD4+ T-cell reaches its
unresponsiveness state when the telomere length reaches about one
half of its initial value. Since the length of telomeres in T-cells
typically shortens with host's age, the process of immunesenescence
includes not only a decline in the CD4+ T-cell count, but also a
reduction in the proliferative capacity of these cells (Romanyukha
and Yashin, 2003). In order to analyze the age-related changes in the
efﬁcacy of IL-2-based therapies, we consider the following instance
from Romanyukha and Yashin (2003) to represent a typical picture of
immunosenescence:Tab
Lym
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IL
IL
IL
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Fig.
con2-fold slowing down of the declining rate of cell production by
the source compartment, 2-fold slowing down of the LT compartment volume, and
 3-fold slowing down of the telomere repeats reduction rate.
For such regimen of functioning of the immune system, the
resulting homeostatic condition (i.e., the uninfected steady-state)
is tabulated in Table 5. Sexually transmitted infection is considered
as the new baseline instance. In Fig. 18, the impact of continued
IL-2 therapy on the viral and lymphocyte dynamics during primary
HIV infection is shown. The long-term management is addressed
in Fig. 19, in which intermittent IL-2 administration combined or
not with HAART is then considered. In all the cases, IL-2 therapy is
initiated right after seroconversion.le 3
phocyte and virological changes from baseline for distinct therapeutic
emes.a
herapy HAART effectiveness
(fp) (%)
HIV-RNA
(copies/ml blood)b
CD4 T-cell count
(cells/mm³ blood)b
ontrol
(no therapy)
– 1.60107 278
-2c – 1.56107 437
-2c+HAART 25.0 1.01107 593
-2c+HAART 50.0 3.59106 815
-2c+HAAR 75.0 6.68105 1105
-2c+HAART 99.5 5.58103 1268
a For a host infected by HIV through the mucosal route initiating therapy after
conversion.
b Relative to day 120 after exposure to HIV.
c Scheme C3.
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sider mucosal exposure to HIV, therapies initiating at day 10, IL-2 therapy based on4. Discussion
In vivo increases in CD4+ T-cell levels during the IL-2 therapy
appear to result from extrathymic expansion of the existing CD4+
T-cell repertoire (Sereti et al., 2001) including a preferential
peripheral expansion of naïve and central memory CD4+ T-cells
(Levy et al., 2003). In fact, simulation experiments based on
continued IL-2 therapies early in the infection course (Figs. 10
and 11) have predicted a remarkable increase in the proliferation
rate of lymphoid CD4+ T-cells. For instance, it raised approximately
50% when continued IL-2 therapy (16 MIUs per day) was con-
sidered whereas the cellular production rate by the thymus
remained unchanged as compared to the control (data not shown).
However, despite the impressive increase in the CD4+ T-cell
proliferation rate, the immunity restoration was very limited,
being restricted to an expansion of about 3.6% in the plasma
CD4+ T-cell count at day 120 (Fig. 10d). Moreover, this increase in
the host immunocompetency could be considered apparent, since
it was exclusively due to the expansion of HIV-infected lympho-
cytes (Fig. 11), which may become impaired to perform their
immunological functions. In this sense, our results could have a
correlation with previous literature, which suggested inability of
the expanded T-cell pool to mediate an effective response to
opportunistic diseases (INSIGHT-ESPIRIT, 2009; Markowitz et al.,
2012; Tavel, 2010).
In the long-term, phase I/II studies demonstrated that inter-
mittent IL-2 administration to HIV-infected patients leads to a
signiﬁcant proliferation of CD4+ T-cells in vivo, often to ranges of
800–1000 cells/mm³, whereas a transient increase in plasma
viraemia that returned to baseline was also noted in the acute
setting of IL-2 administration in vivo. In general, these results were
produced with patients who received some form of antiretroviral
therapy and the increases in CD4+ T-cell counts were typically
more pronounced in treated individuals with baseline CD4+ T-cell
counts 4200 cells/mm³ during the IL-2 therapy (Dybul et al.,
2003; Sereti et al., 2007; Read et al., 2008).
The model, however, failed to reproduce such expected behavior
and did not predict a preferential, signiﬁcant, expansion of naïve
and memory CD4+ T-cells in the long term, as experimentally
observed (Levy et al., 2003; Read et al., 2008). Instead, computa-
tional results indicated that such subpopulations of CD4+ T-cells
should decrease as a result of the IL-2 therapy, this mode predicting
an unfavorable balance between peripheral expansion via enhanced
proliferation and cell death following IL-2 administration.
Case Study 2 allowed functional immunity to be theoretically
assessed in the long-term aiming at verifying whether the lack of a
massive CD4+ T-cell expansion by IL-2 could be related to the lack
of representation of other biological mechanisms, such as those
associated to abnormal and/or persistent levels of immune activa-0 20 40 60 80 100 120
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Table 4
Between-compartment relative changes from baseline for distinct therapeutic schemes during asymptomatic phase.a
Scheme F Monocyte–macrophagecell lineage Naïve CD4 T-cells Memory CD4 T-cells Effector CD4 T-cells HIV RNA
PB LT CNS PB LT PB LT CNS PB LT CNS PB LT CNS
Controlb 109 2314 20.2 23.5 22.4 228 2246 0.036 19.4 27904 0.011 1.65 24.0 0.09
IL-2 alone 1.5 4.59 2.12 -0.50 22.5 13.8 31.5 7.48 −5.56 −21.6 −1.96 −4.55 −7.88 −24.1 4.44
IL−2 alone 2.0 7.34 2.98 −4.95 42.1 27.2 53.9 9.48 −13.8 −37.1 −8.03 −17.2 −10.9 −38.3 −0.44
HAART alone c 166 63.5 278 725 −29.0 189 124 166 −48.6 −88.6 −76.3 −93.4 −86.9 −93.2
HAART+IL-2 1.5 174 65.7 249 895 −26.3 224 126 163 −55.8 13.7 −80.0 −94.8 −88.7 −95.4
HAART+IL-2 2.0 179 67.3 216 1082 −21.8 232 114 150 −63.4 4.76 −83.6 −95.7 −90.2 -97.0
a Averaged data between the 120th and 365th days after initial infection (data in %). Simulations consider sexually transmitted infection, intermittent IL-2 therapy based
on scheme I5 and HAART with effectiveness of 75%. For equation (31), Ω ¼45 days, sr¼50 pg/mm³ and F deﬁned in the 2nd column.
b Cell counts expressed in cells/mm³ and HIV RNA levels in copies/ml10−7.
c Results unchanged for F¼1.5 and 2.0.
M. Joly, D. Odloak / Journal of Theoretical Biology 335 (2013) 57–7872tion due to IL-2 and/or HIV. In this sense, the role of chronic
activation of the immune system by HIV infection was then
investigated by considering the clinical evidence that chronic
T-cell stimulation leads to shedding of IL-2Rα thereby possibly
changing the IL-2 concentration needed for growth stimulation or
activation of apoptotic processes (Abbas et al., 2000). A simple
logistic model for dynamically evaluating IL-2 half-saturation
constants involved in the proposed models for CD4+ T-cell activa-
tion, proliferation and death was then considered to analyze the
impact of intermittent IL-2 therapy in the long-term. However, the
reformulated model remained unable to predict a sustained
increased in the CD4+ T-cell count following IL-2 administration
(Fig. 13c). In fact, IL-2-mediated enhanced proliferation alone may
not be sufﬁcient to account for CD4+ T-cell increases in vivo, since
increased proliferation can be seen even in patients without such
CD4+ T-cell count increases (Read et al., 2008). In this regard, some
authors argued that the increase in survival of CD4+ T-cells
expressing CD25 appears to be the critical mechanism leading to
sustained CD4+ T-cell increases in HIV-infected patients receiving
intermittent IL-2 therapy (Sereti et al., 2007; Read et al., 2008).
If this is true, the proposed model should be expected to fail to
produce a substantial, sustained increase in the CD4+ T-cell count
when long-term intermittent IL-2 therapy is considered, since the
model is based on constant cell death rates. Surprisingly, we did
not detect any plausible correlation between CD4+ T-cell survival
and sustained increases in CD4+ T-cell counts by considering an IL-
2 density-dependent logistic function for dynamically evaluating
natural death rates for the CD4+CD25+ T-cell pool, even after
correcting for other potential contributing factors regulated by key
model parameters associated to IL-2-mediated processes (data not
shown).Since IL-2-induced improvements in the aberrant homeostatic
mechanisms that regulate the activation and differentiation of
CD4+ T-cells may represent an important mechanism in vivo in
patients with HIV infection (Kovacs et al., 1996), simulation experi-
ments were then performed by considering that Fas-mediated
apoptotic mechanisms become more efﬁcient following IL-2
administration whenever the IL-2 availability in the systemic
circulation overcomes a critical threshold that is never achieved
at physiologic conditions (Garibal et al., 2012). Increased baseline
immune activation due to repeated cycles of IL-2 seems to induce
biological changes and alter the characteristics of the CD4+ T-cells
compared to when they had been naïve to IL-2 (Sereti et al., 2007;
Read et al., 2008) and CD4 T-cell expansions were associated with
increased apoptosis rates of T lymphocytes during IL-2 cycles
(Sereti et al., 2001). Hence, we tested the hypothesis that under
such abnormal levels of circulating IL-2, increased rates of CD4+
T-cell apoptosis via the Fas-mediated pathway could be sustained
for a considerable period of time.
Computational results based on this model show a signiﬁcant,
selective, and sustained CD4+ T-cell expansion at scales compar-
able to those observed in vivo following IL-2 therapy (Fig. 14).
Moreover, the expanded peripheral CD4+ T-cells presented a naïve
or central memory phenotype (Table 4) and in most part are
healthy. These results are in concert with experimental data
(Sereti et al., 2007; Read et al., 2008; INSIGHT-ESPIRIT, 2009).
In agreement with Levy et al. (2003), another ﬁnding from this
study was the theoretical demonstration that IL-2 therapy com-
bined with antiretroviral drugs alone (by assuming a HAART
scheme with low fp) or in combination (high fp) has a greater
impact on the lymphocyte rebound than that provided by HAART
alone (Figs. 15b, 16b and Table 4). A pooled analysis of previous
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Fig. 17. Model dynamics for intravenous infection with SI viral strains: (a) syncytium-inducing CXCR4-using viral strains evolutionary model after HIV transmission with
infected blood from an HIV-infected patient at clinical AIDS; (b) plasma HIV RNA level in response to intermittent IL-2, intermittent IL-2+HAART and HAART alone (copies/ml);
(c) the corresponding CD4+ T-cell dynamics (cells/mm³); (d) IL-2 concentration dynamics in the LT following mucosal and intravenous infection (no therapy) (pg/mm³). In (b) and
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compared with HAART alone, had higher CD4+ T-cell counts, lower
viral loads, and a trend towards fewer opportunistic infections and
death (Kovacs et al., 1995, 1996; Levy et al., 2003; INSIGHT-ESPIRIT,
2009). For instance, patients treated with IL-2 and HAART may
achieve an 80% increase in CD4+ T-cell counts above baseline with
the effect of IL-2 corresponding to a global peripheral expansion of
naïve and memory CD4+ T-cells (Levy et al., 2003). In addition,
after discontinuation of IL-2 cycles, CD4+ T-cell responses can be
sustained for up to 8 months in some patients and could be
reinduced by the administration of additional IL-2 (Kovacs et al.,
1996).
Simulation results also agree with several trials conducted
before the HAART era, which did not detect any long-term
deleterious effect of IL-2 on the plasma HIV viral load. Here, slight
variations around the baseline proﬁles are typically produced
depending on the F parameter, which deﬁnes the impact of IL-2
therapy on the Fas-mediated apoptotic pathway activity (Figs. 15a,
16a and Table 4).
Altogether, our results provide theoretical background to the
experimental evidence related to the fact that IL-2 therapy combined
with HAART: (a) may help to restore the host immunocompetency
without a deleterious impact on the antiretroviral efﬁcacy; (b) does
not impact viral load over time, and (c) restores and/or increases
memory responses in patients without antigen challenging (Levy
et al., 2003). Also, the relative decrease in the HIV RNA level provided
by IL-2 therapy after the emergence of SI viral strains (Fig. 16) may
imply a lower degradation of thymic function than that associated to
the untreated case. Hence, at late stages of infection, increased naïve
CD4+ T-cell levels should be favored by enhanced thymic output
in vivo, as initially speculated by De Paoli (2001).
From case study 4, one can see that more virulent scenarios are
produced when the host infection is mediated by the intravenous
route (Fig. 17b and c). Despite the smaller IL-2 concentration in
lymphoid tissue early in the infection course than that associatedto mucosal transmission (Fig. 17d), similar levels of incremental
CD4+ T-cell counts may be achieved early in the infection course
by combining IL-2 therapy with HAART (Figs. 16 and 17).
A simpliﬁed analysis of in vivo evidence for the decline of the
immune system functioning with age is performed in case study 5
by considering a specialized set of parameters of immunosenes-
cence. The distinguishing features of the new baseline (an elderly
patient) included an important change in the viral load pattern,
now presenting a dramatic reduction in the plasma HIV RNA level
as compared to the control (young patient), but similar CD4+ T-cell
counts following the peak of viraemia in both cases (Fig. 18). Such
behavior in the elderly experiencing primary HIV infection results
from a drastic reduction (by 3-fold) of the proliferating CD4+ T-cell
population and lower levels of IL-2 in the LT compartment (by
6-fold at the peak of viraemia and by 2-fold after the acute phase)
than the control instance (young patient).
In opposition to previous conclusions reported herein, the
model does not ensure potential beneﬁts even when continued
IL-2 therapy alone is considered in the elderly. Some deleterious
effect of immunotherapy on virological and immunological res-
ponses was predicted by the model for low-dose IL-2 therapy, as in
therapeutic regimen C1 (Fig. 18), when the critical concentration sr
is not achieved. Interestingly, this latter conclusion was well
supported by experimental data from subjects with advanced
disease and severe impairment in immunocompetency (CD4+
T-cell counts o200 cells/mm³) treated with IL-2, for which lym-
phocyte counts failed to increase and levels of plasma viral load
increased (Kovacs et al., 1995; Dybul et al., 2003). Although the
introduction of antiviral therapy resulted in more sustained
increase in CD4+ T-cell counts, simulation results did not show
either appreciable changes in immunological status after consider-
ing combined treatment (HAART+IL-2) (Fig. 19). Hence, in concert
with Kovacs et al. (1995), it is clear from our data that the use of
IL-2 in patients with low CD4+ T-cell counts (e.g., rapid progressors
or AIDS patients) or declined immunity (elderly patients) may not
Table 5
Model steady-state associated with the elderly individual.
aC Concentration of interleukin-2 in the CNS 1.2610−5 pg mm−3
aL Concentration of interleukin-2 in the LT 3.35 pg mm−3
aP Concentration of interleukin-2 in the PB 4.9410−3 pg mm−3
bC Concentration of interleukin-12 in the CNS 1.0010−2 pg mm−3
bL Concentration of interleukin-12 in the LT 5.60 pg mm−3
bP Concentration of interleukin-12 in the PB 8.2010−3 pg mm−3
cC Concentration of interferon-γ in the CNS 1.3810−7 pg mm−3
cL Concentration of interferon-γ in the LT 1.1010−1 pg mm−3
cP Concentration of interferon-γ in the PB 1.2110−4 pg mm−3
EC Concentration of healthy effector T-cells in the CNS 4.0010−4 cells mm−3
EL Concentration of healthy effector T-cells in the LT 1.09104 cells mm−3
EP Concentration of healthy effector T-cells in the PB 1.20 cells mm−3
MC Concentration of healthy memory CD4 T-cells in the CNS 5.0010−2 cells mm−3
ML Concentration of healthy memory CD4 T-cells in the LT 2.04102 cells mm−3
MP Concentration of healthy memory CD4 T-cells in the PB 1.30102 cells mm−3
NL Concentration of healthy naïve CD4 T-cells in the LT 9.14 cells.mm−3
NP Concentration of healthy naïve CD4 T-cells in the PB 2.97102 cells mm−3
PC Concentration of healthy macrophages in the CNS 23.6 cells mm−3
PL Concentration of healthy macrophages in the LT 7.27103 cells mm−3
YP Concentration of healthy monocytes in the PB 271 cells mm−3
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M. Joly, D. Odloak / Journal of Theoretical Biology 335 (2013) 57–7874provide a signiﬁcant expansion of CD4+ T-cells, as seen in patients
with initially high CD4+ T-cell counts (Levy et al., 2003). Thus,
if intermittent IL-2 therapy has a clinical beneﬁt in patients
with HIV infection, it will most likely be seen in those with
CD4+ T-cell counts 4200 cells/mm³ (Kovacs et al., 1995; Dybul
et al., 2003). These results show that the aging of CD4+ T-cell
system of immunity is a complex phenomenon, which includes
several interrelated processes (Romanyukha and Yashin, 2003).
Limitations of this study include the lack of an explicit analysis
of inter-patient variability with respect to the genetic backgroundof the human being, since it is well established that no two
individuals respond to HIV infection and therapy in quite same
way (Hadjiandreou et al., 2009). In a similar way, intra-patient
variability (e.g., with respect to concurrent infections by other
pathogens (McLean and Nowak, 1992)) may represent another
interesting subject for future research. In this sense, considering
the genetic diversity of HIV may be another natural extension of
this work, since the role of sanctuaries in the evolution of drug
resistance is likely to be even more crucial for multidrug therapies.
Here, the process of generating mutants in one compartment and
Table A.1
Mathematical relationship among model state variables and biological mechanisms.a
#ID 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 Notes
Model state Production (pro) Apoptosis (apo) Death Infection (inf) Cell signaling/Cytokines Recruitment (rec)
Source Activ. Prolif. Diff. Rev. AICD PCD ENV TAT Lysis Age VTC CCF PSVE ISVT CD40 IL-2 IL-12 IFN-γ CNS LT PB
1 AC −lm −lm −pm +lm +lm 1
2 AL +lm −pm +lm +lm −lm 2
3 AP +if −lm −lm −pm +lm −lm +lm 3
4 BC +lm −pm +lm +lm +lm 4
5 BL +lm −lm −pm +lm +lm +lm −lm 5
6 BP −pm −lm +lm 6
7 CC +pm −lm −pm +lm +lm +lm 7
8 CL +pm −lm −pm +lm +lm −lm 8
9 CP +pm −pm −lm +lm 9
10 EC −pm −lm −lm −ma −ma −ma −ma +lm +lm +lm 10
11 EL +lm +lm −pm −pm −lm −lm −ma −ma −ma −ma −ma −ma +lm +lm −lm 11
12 EP −pm −lm −lm −ma −ma −ma +lm +lm −lm +lm 12
13 EC −pm +ma +ma +ma +ma 13
14 EL −ma −ma −pm +ma +ma +ma +ma −lm 14
15 EP −pm +ma +ma +ma −lm +lm 15
16 MC +pm −ma −ma −ma −ma −ma 16
17 ML −lm +pm +pm −ma −ma −ma −ma −ma −ma −ma +lm +lm −lm 17
18 MP +pm −pm −ma −ma −ma +lm 18
19 MC −pm +ma +ma +ma +ma 19
20 ML −ma −ma −pm +ma +ma +ma +ma −lm 20
21 MP −pm +ma +ma +ma +lm 21
22 NL −lm/τ −lm −pm +lm 22
23 NP +lm −pm −lm 23
24 PC −pm −ma +lm +lm/α 24
25 PL −pm −ma +lm/α 25
26 PC −pm +ma 26
27 PL −pm +ma 27
28 VC +pm/te −ma −ma +lm 28
29 VL +pm/te −ma −ma −lm 29
30 VP +pm/te −ma −ma −lm +lm 30
31 YP +lm −pm −ma lm −lm −lm 31
32 θ −lm −lm −lm −lm 32
Abbreviations are as follows: pm: The state variable “row” is subject to the mechanism “column” according to a proportionality model; ma: The state variable “row” is subject to the mechanism “column” according to a mass-action
model; lm: The state variable “row” is subject to the mechanism “column” according to a logisticmodel; /d: The state variable “row” is subject to the mechanism “column” with a time delay of duration d; if: The state variable “row” is
subject to the mechanism “column” according to an independent function.
a Filled rectangles denote interdependence among mechanisms.
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Table B.2
Parameters for the uninfected state (homeostasis).
ca Loss rate of IL-2 due to the proliferation of T-cells 1.6410−4 pg cell−1 day−1 Friedman et al. (2008)
cb Loss rate of IL-12 due to T-cell differentiation into effector cell 1.6410−4 pg cell−1 day−1 b.h.
cc Loss rate of IFN-γ due to maturation of monocytes in macrophages 1.6410−4 pg cell−1 day−1 b.h.
ct Cytokine transport coefﬁcient from the LT to the PB 10−3 h.c.
db Diffusion coefﬁcient through the blood-brain barrier 7.61 day−1 Davson and Segal (1996)
dd Natural death rate for effector T-cells due to the PCD mechanism 2.7710−1 day−1 Perelson et al. (1993)
dM Natural death rate for memory T-cells 9.4910−5 day−1 Abbas et al. (2000)
dN Natural death rate for naïve T-cells 1.8010−4 day−1 Romanyukha and Yashin (2003)
dP Natural death rate for healthy monocytes/macrophages 6.9310−3 day−1 Stites et al. (1994)
ea Clearance/degradation rate of IL-2 1.19 day−1 Friedman et al. (2008)
eb Clearance/degradation rate of IL-12 1.19 day−1 Friedman et al. (2008)
ec Clearance/degradation rate of IFN-γ 3.00 day−1 Friedman et al. (2008)
fb Blood ﬂowrate through the lymphatic tissues 2.50 L day−1 Stites et al. (1994)
fd0 Functional integrity of the FDC network 9.9910−1 b.h.
hcc Collision coefﬁcient between two immune cells 4.3410−4 mm3 cell−1 day−1 b.h.
hvc Collision coefﬁcient between viral particles and immune cells 8.9210−3 mm3 cell−1 day−1 b.h.
kr Reversion rate of effector T-cells to the memory phenotype 2.0910−2 day−1 h.c.
mN0 Maximum number of mitotic cycles performed by naïve T-cells 10 Murray et al. (1998)
mM0 Maximum number of mitotic cycles performed by memory T-cells 8 h.c.
pA IL-2 production rate by proliferating T-cells 5.5810−3 pg cell−1 day−1 Linke-Israeli et al. (1985)
pB IL-12 production rate by resting macrophages 5.0010−4 pg cell−1 day−1 Friedman et al. (2008)
pC IFN-γ production rate by effector T-cells 1.2410−4 pg cell−1 day−1 Friedman et al. (2008)
rC Cellular recruitment coefﬁcient (from PB to CNS) 10−4 day−1 b.h.
rL Cellular recruitment coefﬁcient (from PB to LT) 6.9010−1 day−1 Abbas et al. (2000)
rP Cellular recruitment coefﬁcient (from LT to PB) 3.5010−4 day−1 Sud et al. (2006)
sB IL-12 half-sat, T-cell differentiation into effector cells 5.0010−2 pg mm−3 Friedman et al. (2008)
sc Cytokine half-sat in the CNS 1.0010−4 pg mm−3 b.h.
sC IFN-γ half-sat, activation of resting macrophages 5.0010−2 pg mm−3 Friedman et al. (2008)
sE Half-sat, effector T-cell count in the PB 5 cells b.h.
smax IL-2 threshold above which the AICD mechanism is favored 3.00101 pg mm−3 b.h.
smin IL-2 threshold below which the PCD mechanism is favored 1.5010−1 pg mm−3 b.h.
sn Half-sat, naïve T-cell count in the PB compartment 2.25102 cell mm−3 h.c.
sN Half-sat, naïve T-cell count in the LT compartment 1.13 cell mm−3 h.c.
sP Half-sat, macrophage count in the LT compartment 3.20102 cell mm−3 h.c.
sT Half-sat, overall T-cell count in the LT compartment 3.3310 virus mm−3 Perelson and Nelson (1999)
sY Half-sat, monocyte count in the PB compartment 2.35102 cell mm−3 h.c.
sγ IL-2 half-sat, resting T-cell proliferation 1.50101 pg mm−3 Abbas et al. (2000)
sαγ IL-2 half-sat, activated T-cell proliferation 1.5010−1 pg mm−3 Abbas et al. (2000)
te Time period of the HIV eclipse phase 1 day Nelson et al. (2000)
vC Volume of the CNS 0.125 L Davson and Segal (1996)
vL Volume of the LT 1.50 L Romanyukha and Yashin (2003)
vP Volume of the PB 5.00 L Tuckwell and Le Corfec (1998)
α Duration of the monocyte-macrophage maturation process 7 days Joly and Pinto (2005)
γ T-cell supply model parameter 3 h.c.
η Duration of mitotic cycles, proliferating T-cells 1 day h.c.
φ Maximum proportion of T-cell differentiation into effector cells 60% Sud et al. (2006)
λN0 Maximum production rate of thymocytes 20 cell mm−3 day−1 Wu et al. (2012)
λY0 Maximum production rate of monocytes 20 cell mm−3 day−1 b.h.
τ Duration of the ﬁrst mitotic cycle, antigen-stimulated naïve T-cells 3η Abbas et al. (2000)
ω Duration of the ﬁrst mitotic cycle, reactivated memory T-cells η Abbas et al. (2000)
h.c.: homeostatic condition; b.h.: by hypothesis.
Table B.1
Independent state variables and corresponding initial conditions.
aC Concentration of interleukin-2 in the CNS 1.2010−6 pg mm−3 h.c.
aL Concentration of interleukin-2 in the LT 22.53 pg mm−3 h.c.
aP Concentration of interleukin-2 in the PB 0.01 pg mm−3 Friedman et al. (2008)
bC Concentration of interleukin-12 in the CNS 2.5810−1 pg mm−3 h.c.
bL Concentration of interleukin-12 in the LT 2.79 pg mm−3 h.c.
bP Concentration of interleukin-12 in the PB 1.1510−3 pg mm−3 h.c.
cC Concentration of interferon-γ in the CNS 1.9810−7 pg mm−3 h.c.
cL Concentration of interferon-γ in the LT 2.40 pg mm−3 h.c.
cP Concentration of interferon-γ in the PB 8.1010−4 pg mm−3 h.c.
EC Concentration of healthy effector T-cells in the CNS 2.5410−3 cells mm−3 h.c.
EL Concentration of healthy effector T-cells in the LT 6.68104 cells mm−3 b.h.
EP Concentration of healthy effector T-cells in the PB 10.00 cells mm−3 Essunger and Perelson (1994)
MC Concentration of healthy memory CD4 T-cells in the CNS 3.62102 cells mm−3 h.c.
ML Concentration of healthy memory CD4 T-cells in the LT 5.40102 cells mm−3 b.h.
MP Concentration of healthy memory CD4 T-cells in the PB 5.40102 cells mm−3 Essunger and Perelson (1994)
NL Concentration of healthy naïve CD4 T-cells in the LT 24 cells mm−3 h.c.
NP Concentration of healthy naïve CD4 T-cells in the PB 4.50102 cells mm−3 Essunger and Perelson (1994)
PC Concentration of healthy macrophages in the CNS 620 cells mm−3 h.c.
PL Concentration of healthy macrophages in the LT 6.82103 cells mm−3 b.h.
YP Concentration of healthy monocytes in the PB 460 cells mm−3 Abbas et al. (2000)
θ Functional integrity of the lymphoid tissues 99% b.h.
h.c.: homeostatic condition; b.h.: by hypothesis.
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enough to provide mutants with a selective advantage, may be
repeated several times in the stepwise accumulation of resistant
mutations (Kepler and Perelson, 1998). By adopting a multi-
compartment approach, such as the one proposed in this paper,
one can perform specialized sensitivity analysis or hypothesis
testing about the behavior of HIV infection in an immunologically
privileged site. In particular, to develop a more detailed under-
standing of HIV infection dynamics in the CNS may be important
since the propensity for certain viral isolates to infect the CNS and
mediate neuronal damage, which may be caused by neuronal
interaction with viral proteins released or expressed by the
infected cells, was identiﬁed as one of the major unanswered
questions of HIV dementia (Albright et al., 1999), a serious CNS
complication that affects 20–30% of individuals infected with HIV.
In conclusion, our ﬁndings suggest that the massive, selective
and sustained CD4+ T-cell expansion following IL-2 administration
may be not due to the increased survival of CD4+ T-cells as argued
in the past, but indeed it may be gauged by sustained abnormal-
ities caused by non-physiologic levels of circulating IL-2 on the
Fas-dependent apoptotic pathway (Garibal et al., 2012).Acknowledgments
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Dependent variables and parameters.Appendix A. The model structure
See Table A1.a Rate of activation of T-cells at time t
fd FDC network functional integrity at time t
fSI
Normalized fraction of syncytium-inducing isolates (i.e., R5X4 and X4) of
HIV at time t
mN
Number of mitotic cycles performed by an antigen-stimulated naïve T-cellAppendix B. Model nomenclature and parameter values
See Tables B1–B4.
at time t
mM
Number of mitotic cycles performed by a reactivated memory T-cell at
time t
Ti
Total concentration of T-cells (healthy and infected) in compartment i at
time t
T
i Total concentration of infected T-cells in compartment i at time t
Xi Total concentration of healthy immune cells in compartment i at time t
X
i Total concentration of infected immune cells in compartment i at time t
β Macrophage activation level at time t
λN Production rate of thymocytes at time t
λY Production rate of monocytes at time t
θ Lymphoid tissue degradation rate at time tAppendix C. The cytokine transportation model across the BBB
Cytokines may cross the BBB in a deﬁnite way and, thus, act as a
link between the peripheral immune system and the CNS (Davson
and Segal, 1996). Human and murine IL-1α and murine IL-1
penetrate the BBB more rapidly than albumin (66 kDa), suggesting
peptide binding to receptors on the capillary endothelium (Davson
and Segal, 1996). The uptake of the aforementioned set of cytokines
into mice brains showed PS product (ps) values ranging from 2.36 toTable B.3
Parameters for the infected state.
dIP Natural death rate for infected long-lived cells
dl Death rate of productively infected T-cells due to membrane lysis
dfas Fas-induced apoptosis rate of T-cells
dv Free virus death rate
fcc Efﬁciency coefﬁcient of the cell–cell contact
fP Functional coefﬁcient of infected macrophages
fv Rate of infectious to defective virions
kd Functional degradation rate of lymphoid tissues due to HIV infection
nE Virus production rate by infected effector T-cells
nP Virus production rate by infected macrophages
nM Virus production rate by infected memory T-cells
sv Half-saturation for the HIV degenerative activity on the lymphoid org
h.c.: homeostatic condition; b.h.: by hypothesis.13.510−4 ml/g/min, with ps given by the product of the BBB
permeability (or ﬂux) coefﬁcient pb and the area of capillaries ac
in unit mass of brain (Davson and Segal, 1996). Since the actual
compartment is represented by the brain water volume vbw in
which immune cells and cytokines are concentrated, the transfer
coefﬁcient should be redeﬁned in terms of the actual fraction of the
brain weight fbw that corresponds to the brain water. If it is the
extracellular ﬂuid only, fbw≅0.15; if it is the total water, we have
fbw≅0.75 (Davson and Segal, 1996). By assuming that the unidirec-
tional delivery of large peptides, such as cytokines, from the blood
to brain occurs by diffusion through the BBB, and applying Fick's
Law written on a cytokine concentration basis, we have that the
transport of cytokines into the brain in homeostatic conditions
could in principle be modeled as: (dc/dt)¼(pbac/vbw)(cblood−cbrain),
where c is the cytokine concentration and t is time.
However, all three cytokines presented self-inhibition, and also
cross-inhibition, suggesting transport by a single, saturable
mechanism (Davson and Segal, 1996). In addition, it was found
that about 100% of the labeled material in the blood had remained
intact whereas such parcel in the brain was limited to approxi-
mately 40%, indicating partial breakdown after crossing the BBB
(Davson and Segal, 1996). Hence, a more reasonable model for
cytokine transport into the brain might be (dc/dt)¼(pbac/vbw)
(cblood(1−csat))δ, where δ is the fraction of cytokine that remained
intact after crossing the BBB and csat¼(ctot/(sc+ctot)) is a saturation
term that accounts for the self and cross inhibition among
cytokines, in which ctot denotes the total cytokine concentration
within CNS and sc its corresponding half-saturation constant.1.3810−2 day−1 Essunger and Perelson (1994)
0.50 day−1 Nelson et al. (2000)
10−2 day−1 Sud et al. (2006)
3.10 day−1 Perelson and Nelson (1999)
1.00 b.h.
0.50 b.h.
10−2 Murray et al. (1998)
7.0210−4 day−1 b.h.
3102 virus cell−1 day Essunger and Perelson (1994)
3102 virus cell−1 day b.h.
3102 virus cell−1 day b.h.
ans 3.33104 virus mm−3 b.h.
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Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.jtbi.2013.06.019.References
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